Clinical Trial Update: Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating maraviroc-based prophylaxis to prevent graft-versus-host disease after hematopoietic stem cell transplantation; current status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation | Phase 2 | Status: UNKNOWN